# Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Study · id `cardio:ct-nct01375751` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01375751](<https://clinicaltrials.gov/study/NCT01375751>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01375751

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

## Technical summary

Registry record NCT01375751. Randomized; quadruple masking; primary purpose treatment. Start 2011-08-02 (actual); primary completion 2012-05-16 (actual). Results posted on 2015-09-29.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 168 participants (enrolled count; ClinicalTrials.gov record NCT01375751, source copy `cardio:ctgov-nct01375751-2022-11-15`, retrieved 2026-10-31)
- Started: 2011-08-02 (actual) (ClinicalTrials.gov record NCT01375751, source copy `cardio:ctgov-nct01375751-2022-11-15`, retrieved 2026-10-31)
- Primary completion: 2012-05-16 (actual) (ClinicalTrials.gov record NCT01375751, source copy `cardio:ctgov-nct01375751-2022-11-15`, retrieved 2026-10-31)
- Completion: 2012-05-16 (actual) (ClinicalTrials.gov record NCT01375751, source copy `cardio:ctgov-nct01375751-2022-11-15`, retrieved 2026-10-31)
- Results first posted: 2015-09-29 (ClinicalTrials.gov record NCT01375751, source copy `cardio:ctgov-nct01375751-2022-11-15`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01375751-2022-11-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
- Acronym: RUTHERFORD
- Condition: Hypercholesterolemia, Familial
- Intervention (Biological): Evolocumab
- Intervention (Biological): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 693cfb3ea15746aca437644d3a18e3c13f4a5e2b73e83e4a8497cb98fc043b43
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
